June 4, 2003
"This vaccine is distinct from other approaches in clinical and preclinical development. With a single dose we get measurable and distinct immune responses, and no other vaccine approach has shown this with one dose," said lead researcher Philip Johnson of Columbus Children's Hospital in Ohio.
During the six-month study period, 24 macaques received a single intramuscular injection of the vaccine at varying doses. Dose-dependent antibodies to the transgene product (HIV-1 Gag) increased slowly and were sustained throughout the study. Titer differences between the highest dose groups were insignificant after two weeks, and at six months, more than 70 percent of the macaques had persistent ELISPOT (enzyme-linked immunospot) responses to Gag peptides.
Johnson considers the study results promising. "The International AIDS Vaccine Initiative has done a review and picked our approach as one of several that they are pushing into human clinical trials this year," said Johnson. In October, Phase I trials are due to begin.
05.10.03; Vol. 361: P.1627; Roxanne Nelson